Position in SRZN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$16,424,559
-$2,012,721 QoQ
Shares Held
632,931
0.0% QoQ
Ownership
5.39%
of shares outstanding
% of Portfolio
0.50%
of 13F equity value
Holder Rank
#6
of 70 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SRZN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Venrock Adviser, LLC holds $3,294,790,938 across 31 Biotechnology names. SRZN ranks #28 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
8,493,321 | $1,127,318,496 | |
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
4,148,428 | $394,805,892 | |
| 3 | ERAS |
Erasca, Inc.
|
17,891,812 | $327,777,995 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,985,448 | $265,048,073 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,180,000 | $115,026,400 | |
| 6 | OCUL |
Ocular Therapeutix, Inc
|
10,346,926 | $101,606,813 | |
| 7 | DMRA |
Damora Therapeutics, Inc.
|
3,603,595 | $93,729,505 | |
| 8 | SVRA |
Savara Inc
|
14,745,943 | $90,835,008 |
All Filings in SRZN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $16,424,559 | 632,931 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $18,437,280 | 632,931 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $14,304,240 | 632,931 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,155,315 | 632,931 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $5,658,403 | 632,931 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $7,379,975 | 632,931 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||